Dariusz Wolowiec
Overview
Explore the profile of Dariusz Wolowiec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Korycka-Wolowiec A, Wolowiec D, Lawnicka H, Robak T
Expert Opin Drug Saf
. 2025 Feb;
:1-13.
PMID: 39991898
Introduction: In recent years, chronic lymphocytic leukemia (CLL) treatment has changed dramatically. Chemoimmunotherapy with fludarabine/cladribine, cyclophosphamide, and rituximab have been almost completely replaced by targeted therapies with small molecules, such...
2.
Kosmaczewska A, Ciszak L, Frydecka I, Pawlak E, Szteblich A, Wrobel T, et al.
Pol Arch Intern Med
. 2025 Feb;
PMID: 39950487
Introduction: A unique feature of chronic lymphocytic leukemia (CLL) is the increased number of circulating T cells preventing malignant B cells from undergoing apoptosis. Dysregulated expression of p27Kip1 and cyclin...
3.
Ciszak L, Kosmaczewska A, Pawlak E, Frydecka I, Szteblich A, Wolowiec D
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519258
Beyond the essential role of p27 and cyclin D2 in cell cycle progression, they are also shown to confer an anti-apoptotic function in peripheral blood (PB) lymphocytes. Although the aberrant...
4.
Marchwicka A, Nowak K, Satyr A, Wolowiec D, Marcinkowska E
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047477
(1) Hematological malignancies are characterized by an immortalization, uncontrolled proliferation of blood cells and their differentiation block, followed by the loss of function. The primary goal in the treatment of...
5.
Kubiak A, Ziolkowska E, Korycka-Wolowiec A, Robak T, Wolowiec D
Adv Clin Exp Med
. 2022 Apr;
31(9):1023-1033.
PMID: 35467089
Background: Venetoclax (VEN), a highly selective BCL-2 inhibitor, is successfully used in the treatment of chronic lymphocytic leukemia (CLL). The purine analogue - cladribine (2-CdA) - is also administered to...
6.
Karabon L, Andrzejczak A, Ciszak L, Tomkiewicz A, Szteblich A, Bojarska-Junak A, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831232
In our previous study, while chronic lymphocytic leukemia (CLL) cases showed higher levels of B and T lymphocyte attenuator (BTLA) mRNA compared to controls, lower BTLA protein expression was observed...
7.
Urbanowicz I, Wolowiec D, Wysoczanska B, Lacina P, Jonkisz A, Nahaczewska W, et al.
Adv Clin Exp Med
. 2021 May;
30(5):499-506.
PMID: 33982453
Background: NF-κB is an essential player in cancer biology, especially in tumor development, due to its constitutive activation, and because a four-base deletion (ATTG) in the NF-κB1 promoter region at...
8.
Jasek M, Bojarska-Junak A, Sobczynski M, Wagner M, Chocholska S, Rolinski J, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33036273
Interactions between APRIL (TNFSF13) and its receptor TACI (TNFRSF13B) are implicated in providing survival benefits for chronic lymphocytic leukaemia (CLL) cells. Here we explored the relationship between and SNPs and...
9.
Korycka-Wolowiec A, Wolowiec D, Robak T
Expert Opin Drug Saf
. 2020 Sep;
19(11):1377-1393.
PMID: 32946324
Introduction: Conventional treatment for mantle cell lymphoma (MCL) patients includes regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation with autologous stem cell transplantation and rituximab maintenance....
10.
Ussowicz M, Marcel V, Nguyen Van Long F, Kazanowska B, Diaz J, Wolowiec D
Adv Clin Exp Med
. 2020 Feb;
29(1):107-113.
PMID: 32011831
Background: Dysregulation of ribosome biogenesis and alteration of ribosome composition, including alteration in ribosomal RNA (rRNA) 2'-O-ribose methylation, can play a role in malignant transformation and cancer progression. Several studies...